DESIGNING AND OPTIMIZATION OF NAPROXEN SODIUM DEFORMABLE VESICULAR SYSTEMS THROUGH FACTORIAL DESIGN: BOX BEHENKEN MODEL by GUPTA, NAVEEN & JAIN, SHAILESH
 
 
DESIGNING AND OPTIMIZATION OF NAPROXEN SODIUM DEFORMABLE VESICULAR SYSTEMS 
THROUGH FACTORIAL DESIGN: BOX BEHENKEN MODEL 
Original Article 
 
NAVEEN GUPTA1*, SHAILESH JAIN2 
1,2
Received: 28 Nov 2020, Revised and Accepted: 20 Jan 2021 
School of Pharmacy, Madhyanchal Professional University, Bhopal, India 
Email: naveenmpharm@gmail.com 
ABSTRACT 
Objective: The objective of this investigation was to develop and statistically optimize deformable vesicles such as transfersomes and transethosomes 
of Naproxen sodium by employing 33
Methods: The levels of the drug, phosphatidylcholine, and span 80 (independent variables) were varied to study the influence on vesicle size and % 
entrapment efficiency (dependent variables) of transfersomes and for transethosomes, the levels of phosphatidylcholine, ethanol, and span 80 were 
selected as independent variables Second-order quadratic polynomial equation, 2D and 3D contour plots represented the relationship between 
variables and desired response. The optimization process was carried out using desirability plots and point prediction techniques. 
factorial designs through software Design expert version 12 (Box–Behnken design) for dermal delivery. 
Results: Results of the present study demonstrated that optimized transfersomes and transethosomes showed vesicle sizes of 114.91 nm and 
102.91 nm respectively, while entrapment efficiency of 80.11 % and 86.97%, respectively. Both formulations showed high zeta potential values 
indicating the stability of the optimized formulation. ANOVA statistical results showed a significant difference (P<0.05). 
Conclusion: The results indicated that the independent variable plays a crucial role in optimizing a formulation that can be used for further research 
studies. Present preliminary study data provided strong evidence that the optimized deformable vesicular formulations through box Behnken factorial 
design can be a potentially useful drug carrier for naproxen sodium dermal delivery with minimum vesicle size and efficient entrapment efficiency. 
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INTRODUCTION 
Rheumatoid arthritis is a major cause of disability, particularly in 
older individuals, the symptoms and signs of arthritis include pain, 
stiffness, swelling, muscle weakness, and limitation of movement of 
the joints [1]. Non-steroidal anti-inflammatory drugs like Naproxen 
sodium are an effective drug for the treatment of Arthritis. The anti-
inflammatory effect of NSAIDs is due to cyclooxygenase inhibition 
and the consequent reduction of prostaglandin synthesis leads to 
unfavorable side effects like GIT disorders, renal toxicity, 
hepatotoxicity, cardiovascular risks via systemic administration. So 
the urgent need is to develop a drug delivery system with enhanced 
target place localization and sustained drug release with minimum 
side effects. Designing a controlled and sustained release pattern of 
a drug relies on proper carrier selection, such as nanosome [2]. 
Several attempts have been made in the past to address this issue 
but each has its limitations. One strategy is topical delivery of drugs 
which has many advantages such as avoidance of hepatic first-pass 
metabolism, improved patient compliance, and ease of access [3]. 
Numerous approaches are utilized to enhance the effectiveness of 
the material for permeating through the skin such as penetration 
enhancers, iontophoresis, sonophoresis, etc. But due to the rigid skin 
barrier drugs have to face resistance in permeation also it shows an 
unpredictable drug release. Penetration enhancers and solvents 
irritation. The use of lipid vesicular carriers such as non-ionic 
surfactant-based niosomes and liposomes can overcome the 
filtration problem and penetrate the skin barrier along the 
transcutaneous moisture gradient [4]. 
The drawbacks associated with conventional carriers can be 
overcome by phospholipids-based colloidal drug delivery systems 
with high drug entrapment and penetration ability. These systems 
due to the biocompatible and biodegradable nature of phospholipids 
have gained much attention in recent times. The first such approach 
was the skin delivery of triamcinolone liposomes [5]. But fewer the 
flexibility of liposomal formulations restricts them to reach deeper 
layers of the skin [6, 7]. Then Cevc introduced the concept of 
deformable vesicle transfersomes, which are capable of penetrating 
deeper into the skin by squeezing themselves; transfersomes are 
liposomes that contain edge activators including Tweens, span, 
sodium cholate, and sodium deoxycholate. These edge activators 
destabilize the bilayer lipid membrane of liposomes and increase the 
flexibility of vesicles to reach the deep inner dermal layer [8, 9]. 
Ethosomes are vesicular carriers developed by Touito et al. [10], 
which consist of phospholipid, ethanol, and water. Ethosomes 
increase skin permeation due to the effect of ethanol on the lipid 
bilayer and increasing fluidity of skin stratum corneum lipid [11]. 
The transethosomes are composed of both ethanol and edge 
activators hence they have features of ethosomes and transfersomes 
which promise to be a better carrier for topical delivery. 
Incorporation in a gel system will enhance the permeation and leads 
to localization of the drug at the target site for desired sustained 
action with minimum side effects. and good rheological properties.  
Various formulation factors play a crucial role in the formulation of these 
vesicles such as the concentration of phospholipid, edge activator, 
ethanol, drug amount, and many others. They directly affect the 
structure and efficiency of vesicles. The incorporation of an appropriate 
excipient in optimum concentration is a very important step in designing 
a formulation batch with respective therapeutic goals. This research 
focuses on the development and statistical optimization of vesicular 
carrier’s formulation batches through experimental factorial design 
using screened factors and their levels which directly affect the 
therapeutic goals. For identifying the optimum formula, different 
independent variables that directly affect the properties of vesicles were 
studied by factorial design (Design Expert) software. The optimized 
formula by point prediction method is decided through experimental 
software. Then further experimentation and evaluation will be carried 
out in the next phase of research. 
MATERIALS AND METHODS 
Materials 
Naproxen Sodium was received as a gift sample from Intas 
pharmaceuticals (Rangpo, Sikkim), Carbapol 940 was purchased 
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from oxford laboratories, Mumbai, Span 80 was purchased from 
oxford laboratories, Egg Phosphatidylcholine was obtained from 
Doosan corporation (Korea) All of the solvents and chemicals were 
of the HPLC and analytical grades.  
Experimental methods 
Method of preparation of naproxen sodium loaded transfersomes 
Rotary evaporation-sonication method 
Egg Phosphatidylcholine and edge activator (surfactant) were 
dissolved in chloroform and methanol in a round bottom flask 
(RBF). The ratio of chloroform to methanol was 2:1 v/v. through 
rotary flash evaporator solvent evaporation results in the formation 
of a thin film. water is used as a hydrating medium for 1 h at room 
temperature for hydration of formed film, which resulted in 
multilamellar film vesicles. These vesicles are converted into small 
unilamellar vesicles through ultrasound cavitation and probe 
sonicator [12, 13].  
Method of preparation of naproxen sodium loaded 
transethosomes 
The cold method is used for preparing transethosomes, Egg 
Phosphatidylcholine was dissolved in ethanol in a conical flask with 
constant stirring at 700 rpm. The temperature of this alcoholic 
mixture was maintained at 30 ° C. Drug and Span 80 were dissolved 
in water. This aqueous phase was then added to the alcoholic phase 
slowly in a fine stream with constant stirring at 700 rpm in a closed 
vessel. It was stirred for an additional 5 min. The system was kept at 
30 ° C throughout the preparation. Size reduction was done by probe 
sonication for 5 min at RT. The selection of a method for the 
preparation of transethosomes was based on percent entrapment 
efficiency, stable transethosomal formulations can be achieved 
through the cold method [14]. 
Experimental factorial design: box behenken 
Optimization of process parameters variables 
The process of rotary vacuum evaporation were varied by varying 
the process variables to investigate their effect on the characteristics 
of carrier systems. The process variables Temperature and Rotation 
per minute (RPM) were varied based on 2 factors, 3 levels of general 
factorial design. and experimental trials were performed on all 
batches and based on the quality of film produced, the process was 
optimized [15, 16]. 
Experimental design for the formulation of naproxen sodium 
loaded transfersomes 
The optimization of Naproxen Sodium Transfersomes was done by 
Design Expert, Version 12, Stat-Ease Inc. Minneapolis, USA) using 
three factors at three levels. It provides a rationale for 
understanding the possible interaction(s) among both independent 
and dependent variables and helps in selecting 'optimum' 
formulation in lesser experimental time. The design will help to 
identify the positive or negative effect of a different variable on 
desired responses. (X1) Phosphatidylcholine (mg) was taken as the 
first independent variable, (X2) Span 80 (mg) as the second 
independent variable and (X3) Naproxen sodium (mg) was selected 
as the third independent variables for Transfersomes. These 
variables varied at three levels, low level (-1), medium level (0), and 
high level (+1). Vesicle size (nm) (Y1) and % entrapment efficiency 
(Y2
Experimental design for the formulation of naproxen sodium 
loaded transethosomes 
) were selected as dependent (Response) variables [17]. 
Phosphatidylcholine (mg) (X1) was taken as the first independent 
variable, Ethanol % (X2) was selected as the second independent 
variable, and (X3) Span 80 (mg) as the third independent variables. 
These variables varied at three levels, low level (-1), medium level 
(0), and high level (+1). The amount of drugs were kept constant. 
Vesicle size (nm) (Y1) and % entrapment efficiency (Y2
Characterization of deformable vesicles 
) were 
selected as dependent (Response) variables. 
Vesicle size and zeta potential 
The formulated vesicles (0.1 ml) were diluted (100 times) with 
phosphate buffer (pH 6.8) for vesicle size and zeta potential analysis. 
Each formulation sample (0.1 ml) was diluted (100 times) with 
phosphate buffer (pH 6.8), and the size analysis was performed at 25 
° C with an angle of detection of 90 ° C. The mean vesicle size and 
zeta potential were evaluated using a Particle size analyzer and Zeta 
sizer (Horriba Instruments Ltd). The optimized formulation was 
characterized by a zeta potential value to reveal the stability of the 
formulation [18]. 
Determination of entrapment efficiency 
For estimation of the entrapped drug in the prepared vesicle 
formulation, the unentrapped drug is separated by cooling 
centrifugation (7000×gm) at 4 °C using a cooling centrifuge for 60 
min. Then washing through 40 ml PBS (pH 7.4). The supernatant is 
collected and the quantity of the unentrapped drug was estimated 
by UV spectrophotometer at 271 nm, formula for calculating % 
entrapment efficiency is as follows [19]. 
% Entrapment ef�iciency
= Total amount of drug added 
− Amount of unentrapped drug
/Drug added x 100  
RESULTS AND DISCUSSION 
Optimization of process parameters variables 
During experimental optimization, it is seen that lower speeds of 
instruments increase the time of contact of the film with the hot water 
used for the formation of a film, at higher speeds, sufficient time was 
not available for the lipid to form film and liquid to gel transitions of 
the lipid is difficult to happen this improper distribution of heat leads 
to the formation of the uneven film. The hydration of vesicles was 
affected by different temperatures. When the high temperature is 
selected for the process, the stability and appearance of vesicle film 
are not good however, at low temperature a thin film formed, which 
was uniform and translucent in appearance. Hence, the most 
appropriate temperature is 50 °C. Finally, it was observed that at 50 °C 
temperature and 80 rpm a thin film formed, which was uniform, good 
in appearance with good stability. 
 
Table 1: Effect of rotation speed and temperature for hydration on the trial batches 
Formulation (X1 (X) temp ( °C) 2  Condition of formed film) Rpm * 
Trial 1 50 100 Thin lipid film formed but not rigid and uniform in appearance 
Trial 2 70 100 A bumpy film with entrapped air bubbles  
Trial 3 50 80 The rigid and translucent lipid film was formed with good stability 
Trial 4 60 100 A bumpy film with entrapped air bubbles 
Trial 5 60 80  The rigid film was formed, but less stability 
Trial 6 50 60 Thin lipid film formed but not rigid and uniform in appearance 
Trial 7 70 80 Film not formed 
Trial 8 60 60 Thin lipid film formed but not rigid and uniform in appearance 
Trial 9 80 80 Film not formed 
*Average of three determinations±standard deviation  
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Statistical analysis of the data and optimization 
(Transethosomes) 
The responses were fitted into various mathematical models using 
Design-Expert Version 12 software. The best fit model was decided 
based on the high values of multiple correlation coefficient (R2), 
adjusted R2, and predicted R2
  
 and low values of standard deviation 
(SD),. To evaluate the effect of variables on each response, the 
responses were analyzed to multiple linear regression analysis to 
generate a second-order quadratic polynomial equation. 
Table 2: Experimental runs, independent variables, and measured response of 33 
 
full factorial experimental design for transethosomes 
X X1 X2 Y3 Y1  2 
Run A: Phosphatidylcholine 
(mg) 




1 70 40 20 139.76±2.25 55.23±0.23 -20±0.31 
2 90 30 20 77.23±4.01 73.82±1.24 -30±1.55 
3 70 30 15 112.21±3.54 79.25±0.58 -35±0.66 
4 110 30 25 101.11±1.48 75.13±0.78 -32±0.62 
5 70 30 25 63.21±2.34 57.39±2.10 -24±0.85 
6 70 20 20 110.21±4.21 72.34±3.01 -31±1.58 
7 90 40 15 199.36±1.52 70.21±2.01 -30±1.27 
8 90 30 20 77.21±3.21 74.42±0.98 -28±0.98 
9 90 40 25 126.81±1.56 58.87±0.65 -25±0.81 
10 90 30 20 76.23±2.56 73.82±0.47 -30±0.84 
11 110 40 20 170.12±1.56 63.74±1.54 -25±1.75 
12 90 20 25 132.21±2.58 73.41±0.75 -27±0.36 
13 110 20 20 145.32±0.31 88.62±0.35 -31±0.87 
14 110 30 15 140.58±0.21 85.81±0.81 -29±1.25 
15 90 20 15 145.86±1.28 96.14±0.63 -34±1.66 
*Average of three determinations±standard Deviation  
 
Vesicle size analysis 
Vesicle size plays an important role in skin permeation. Smaller vesicular 
size (200 nm) facilitates the deformable vesicles to pass through the 
small pores of the skin leading to more enhanced skin permeation. The 
average vesicle size of all 15 experimental runs is 121.62 nm, with values 
lying between the minimum and maximum of 63.21±2.34 nm 
(Formulation 5) and 199.36±1.52 nm (Formulation 7), respectively. 
Vesicle size second-order quadratic polynomial equation 
Y1 = 76.89 + 16.47X1 + 12.80X2 −  21.83X3 −  1.19X1X2
+ 2.38X1X3 − 14.72X2X3 + 8.84X1 2 + 55.62X2 2
+ 18.55X3 2 
Where Y1 is Response 1: Vesicle size (nm), X1 is Phosphatidylcholine 
(mg), X2 is Ethanol (%), X3  is 
As per the Quadratic second-order polynomial equation, the 
phosphatidylcholine is showing a positive effect and the surfactant is 
exhibiting a negative effect on vesicle size. It was observed that the 
vesicle size of transethosomes was increased with an increase in the 
concentration of phosphatidylcholine. The result shows that vesicle 
size was increased from 63.21±2.34 nm (formulation 5) to 
170.12±1.56 nm (formulation 11) when phosphatidylcholine was 
increased from 70 mg (formulation 5) to 110 mg (formulation 11). 
Surfactant also plays a very important role in vesicle size as edge 
activator. The result shows that Span 80 presented an inverse effect on 
vesicle size. Vesicle size of prepared transethosomes was decreased on 
increasing the Span 80 from 15 mg to 25 mg. Formulation 7 having 
Span 80 15 mg presented vesicles size of 199.36±1.52 nm while 
formulation 5 presented vesicles size of 63.21±2.34 nm which 
comprised of 25 mg of Span 80. Similarly, formulation 15 (Span 80, 15 
mg) presented vesicles size of 145.86±1.28 nm while formulation 4 
(Span 80, 25 mg) exhibited vesicles size of 101.11±1.48 nm [20, 21]. 
Span 80 (mg)  
Entrapment efficiency analysis 
The entrapment efficiency of all the formulation was lying in between 
a minimum and maximum value of (Formulation1) 55.23and 
(Formulation 15) 96.14±0.63% with the average value of 73.21 %  
Entrapment efficiency second-order quadratic polynomial 
equation 
Y2 = 74.02 + 6.147X1 − 10.31X2 −  8.33X3 −  1.94X1X2 + 2.79X1X3 
+ 2.85X2X3 − 2.15X1 2 − 1.89X2 2 + 2.52X3 2 
Where Y2 is Response 2: Entrapment efficiency (%), X1 
is Phosphatidylcholine (mg), X2 is Ethanol (%) and X3  is 
A positive value before a factor in the response equation denotes a 
positive impact that favors optimization, while a negative value 
indicates a negative impact between the factor and the response. 
Results show that the concentration of phosphatidylcholine is 
showing a positive effect on entrapment efficiency while the other 
two variables ethanol and Span 80 were found to exhibiting a 
negative effect on the entrapment efficiency of the drug. the 
concentration of phosphatidylcholine was showing a positive effect. 
Formulation 13 containing 110 mg of Phosphatidylcholine had 
exhibited entrapment efficiency of 88.62±0.35 % on comparison 
with formulation 1 possessing 80 mg of Phosphatidylcholine 
showing an entrapment efficiency of 55.23±0.23%. The gradual 
increase of entrapment efficiency with an increase in the 
concentration of phosphatidylcholine is because of the inherent 
lipophilic character of naproxen sodium as the lipophilic drug would 
be attracted towards the lipophilic phase and get deposited over 
there. Ethanol presented an inverse effect on the entrapment 
efficiency of naproxen sodium in transethosomes. Formulation 15 
(ethanol 20%) presented an entrapment efficiency of 96.14±0.63%, 
while formulation 1 having ethanol 40% presented an entrapment 
efficiency of 55.23±0.23%. Similar results were obtained for 
formulation 13 and 9. Formulation 1 (ethanol 20%) presented 
entrapment efficiency of 88.62±0.35% and formulation 9 (ethanol 
40%) presented entrapment efficacy of 58.87±0.65%. This could be 
due that at a higher ethanol percentage; vesicles become leakier 
[22]. Surfactant also plays a very important role in Entrapment 
efficiency as edge activator. Entrapment efficiency decreased on 
increasing the concentration of Span 80 Formulation15 (Span 80, 15 
mg) presented entrapment efficiency of 96.14±0.63% while 
formulation 5 (Span 80, 25 mg) presented entrapment efficiency of 
57.39±2.10%. Similar results were obtained between formulation 14 
(entrapment efficiency 96.14±0.63%) and formulation 9 
(entrapment efficiency 58.87±0.65%). The decrease in entrapment 
efficiency with an increase in the concentration of Span 80 is 
because of the coexistence of micelle structure with vesicles in the 
formulation; micelles usually exhibit low entrapment efficiency as 
compared to vesicles [23]. 
Span 80 
(mg)  
Zeta potential measurement 
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Zeta potential of prepared transethosomes is in the range of-
20±0.31 mv (Formulation 1) and-34±1.66 mv (Formulation 15) 
which suggest relative stability of vesicles with minimum 
aggregation properties. The highest Zeta potential of vesicles is-
34±1.66 mv (Formulation 15). 
Analysis of variance (ANOVA) was applied to determine the 
statistical significance and the magnitude of the main effects of each 
variable and their interactions. Counterplots are generated for 
independent factors. The ANOVA table establishes the sufficiency of 
the model (i.e., p<0.05). The result of the p-value is less than 0.05 for 
all the response factors signifying that the models are significant. 
Comparison of the experimental and predicted responses. These 
data showed that most of the predicted values are nearly similar to 
the experimental values. These indicated the excellent ability of the 
experimental design employed for the optimization of 
transethosomal formulation of Naproxen sodium. The predicted 
R2values were in agreement with the adjusted R2
ANOVA for vesicle size (Response 1) 
 values in all 
responses. The relationship between the dependent and 
independent variables was further elucidated using 2D contour plots 
and 3D response surface plots. Desirability and graphical 
optimization technique were utilized for generating formulation 
with the desired responses. The 3D response surface plots are useful 
to understand the effect of interactions between the factors on a 
single response. 
The result of P-values is 0.0001 (Significant) the Model F-value is 
1811.82 showing that the model is significant. P-values less than 
0.05 confirm the significance of the model. Model is not significant 
when values are greater than 0.1000. The Predicted R² of 0.9955 
agrees with the Adjusted R² of 0.9991, the difference is less than 0.2.  
ANOVA for entrapment efficiency (%) (Response 2) 
The result of P-values is 0.0001 (Significant) the model F-value is 
1202.04 showing that the model is significant. P-values less than 
0.05 confirm the significancy of the model. Model is not significant 
when values are greater than 0.1000. The Predicted R² of 0.9944 
agrees with the Adjusted R² of 0.9987; the difference is less than 0.2 
Selection of the optimum formula 
Further in this study, the point prediction method of Box–Behnken 
design was utilized for the optimization of transethosomes 
formulation. The optimized formula desirability function comes 
higher ie near to 1 confirms the suitability of the formulations. 
Further, the zeta potential (fig.) value of optimized formulation was 
found to be-35 mV; the optimized formulation so produced will be 
further evaluated for vesicles morphology, in vitro release study, 
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Fig. 1: Transethosomes factorial design (Box Behnken) 
Vesicle size (nm): 2D contour plot (1A). 3D Surface Contour plot 
(1B). Cube Plot (1C) 
Entrapment efficiency (%): 2D contour plot (2A). 3D Surface 
Contour plot (2B). Cube Plot (2C) 
Statistical analysis of the data and optimization (Transfersomes) 
The responses were fitted into various mathematical models using 
Design-Expert Version 12 software. The best fit model was decided 
based on the high values of multiple correlation coefficient (R2), 
adjusted R2, and predicted R2
Vesicle size analysis 
 and low values of standard deviation 
(SD),. To evaluate the effect of variables on each response, the 
responses were analyzed to multiple linear regression analysis to 
generate a second-order quadratic polynomial equation. 
The average vesicle size of all 15 experimental runs was found to 
140.20 nm, with values lying between the minimum and maximum 
of 114.49±1.54 nm (Formulation 2) nm and 174.65±0.89 nm 
(Formulation 10), respectively. 
  
Table 3: Experimental value obtained through point prediction method 
Composition Optimized level  Response Predicted value Experimental value* 
Phosphatidylcholine (mg) 90.07 Vesicle size (nm) 103.19 102.91 
Ethanol (%) 25.07 Entrapment efficiency 
(%) 
86.62 86.97 
Span 80(mg) 16.53 
 
Table 4: Experimental runs, independent variables, and measured response of 33 
 
full factorial experimental design for transfersomes 
X X1 X2 Y3 Y1  2 
Run A: Naproxen sodium B: Phosphati dylcholine C: Span 80 Vesicle size* Entrapment efficiency* Zeta potential* 
 mg mg Mg Nm %  
1 35 80 24 146.38±0.23 78.06±0.11 -32±0.59 
2 35 60 30 114.49±1.54 75.92±1.53 -31±1.65 
3 35 60 18 136.54±0.58 59.17±1.25 -23±1.51 
4 20 60 24 134.21±1.56 68.73±1.56 -28±0.88 
5 20 80 30 123.32±1.11 89.66±0.89 -36±1.81 
6 50 80 18 148.67±2.54 51.46±1.65 -23±1.11 
7 20 100 24 139.34±0.78 77.23±0.23 -30±0.52 
8 35 80 24 146.38±0.56 74.31±1.65 -31±1.63 
9 35 80 24 146.38±2.10 76.48±0.45 -32±0.41 
10 20 80 18 174.65±0.89 51.13±0.82 -22±0.54 
11 35 100 30 119.23±0.65 89.96±1.11 -37±1.65 
12 50 100 24 144.23±0.62 67.64±1.53 -29±1.55 
13 50 60 24 126.16±0.35 56.34±0.45 -23±0.99 
14 50 80 30 135.33±1.52 70.82±2.54 -29±0.67 
15 35 100 18 167.77±0.45 53.46±0.89 -25±1.77 
*Average of three determinations±standard Deviation  
 
Vesicle size quadratic second-order polynomial equation 
Y1 = 146.38 − 2.14125X1 + 7.39625X2 − 16.9075X3+3.235X1X2
+ 9.4975X1X3 – 6.6225X2X3 + 0.295X1 2
− 10.69X2 2 − 1.1825X3 2 
Where Y1 is Response 1: Vesicle size (nm), X1 is Naproxen sodium 
(mg), X2 is Phosphatidylcholine mg), X3  is 
As per the second-order quadratic polynomial equation, the 
phosphatidylcholine is showing a positive effect on vesicle size, and 
surfactant and drug concentration were exhibiting a negative effect 
on vesicle size. The result showed that the vesicle size of 
transfersomes was increased with an increase in the concentration 
of phosphatidylcholine formulation 15 with phosphatidylcholine 
(100 mg) has a high vesicle size of 167.77±0.45 also formulation 10 
with phosphatidylcholine (80 mg) has a high vesicle size of 
174.65±0.89. Surfactant also plays a very important role in vesicle 
size as edge activator. It was observed that Span 80 presented an 
inverse effect on vesicle size formulation 10 with span 80 (18 mg) 
has a high vesicle size of 174.65±0.89 also formulation 15 with span 
80 (18 mg) has a high vesicle size of 167.77±0.45. As the drug 
concentration reaches the lowest vesicle size becomes highest for 
example formulation 10 with Naproxen sodium (20 mg) has a high 
vesicle size of 174.65±0.89.  
Span 80(mg)  
The surfactants destabilize vesicular bilayer reduces interfacial 
tension hence enhances bilayer elasticity, hence leads to a decreased 
particle size. For skin delivery, small particle size is of importance for 
skin penetration and drug deposition [24]. New research shows a 
mechanistic picture of vesicle solubilization formation and concluded 
that surfactant-containing bilayers, at certain lipid/surfactant ratio, 
spontaneously un/curve and open or close to optimizing edge tension 
[25]. In transfersomes incorporation of edge activators in low 
concentration results in vesicle size growth [26]. 
Entrapment efficiency analysis 
The entrapment efficiency of all the formulation found in between a 
minimum and maximum value of (Formulation10) 51.13±0.82 % and 
(Formulation 11) 89.96±1.11 % with the average value of 69.36 %.  
Entrapment efficiency second-order quadratic polynomial 
equation 
Y2 = 76.2833 − 5.06125X1 + 3.51625X2 + 13.8925X3 + 0.7X1X2
− 4.7925X1X3 + 4.9375X2X3 − 6.32917X1 2
− 2.46917X2 2 − 4.18667X3 2 
Where Y2 is Response 2: Entrapment efficiency (%), X1 is Naproxen 
sodium (mg), X2 is Phosphatidylcholine (mg), X3  is 
Results showed that the concentration of phosphatidylcholine and 
span 80 were showing a positive effect on entrapment efficiency, 
while the naproxen sodium was found to exhibiting a negative effect 
on the entrapment efficiency of the drug. The result shows that the 
entrapment efficiency of transfersomes was increased with an 
increase in the concentration of phosphatidylcholine formulation 11 
with phosphatidylcholine (100 mg) shows high entrapment 
efficiency of 89.96±1.11. Surfactant also plays a very important role 
Span 80(mg). 
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in Entrapment efficiency as edge activator. Entrapment efficiency 
increases on increasing the concentration of Span 80 Formulation11 
(Span 80 30 mg) presented high entrapment efficiency of 
89.96±1.11% while formulation 5 (Span 80 30 mg) presented high 
entrapment efficiency of 89.66±0.89%. As Naproxen sodium 
concentration decreases entrapment efficiency increases. As the 
drug concentration reaches the lowest entrapment efficiency 
becomes highest for example, formulation 5 with Naproxen sodium 
(20 mg) has a high Entrapment efficiency of 89.66±0.89%  
Zeta potential measurement 
Zeta potential values of prepared transfersomes is in the range of-
22±0.54 mv (Formulation 10) and-37±1.6554 mv (Formulation 11) 
which suggest relative stability of vesicles with minimum 
aggregation properties Highest Zeta potential of vesicles is-
37±1.6554 mv (Formulation 11). 
Analysis of variance (ANOVA) 
The ANOVA table confirms the adequacy of the model (i.e., p<0.05). 
The p-value is less than 0.05 for all the response factors indicating 
that the models are significant. These data showed that most of the 
predicted values were close to the experimental values. These 
indicated the excellent prognostic ability of the experimental design 
employed for the optimization of transfersomal formulation of 
Naproxen sodium. The predicted R2values were in reasonable 
agreement with the adjusted R2
ANOVA for vesicle size (Response 1) 
values in all responses. 
The result of P-values is 0.0002 (Significant) the Model F-value is 
53.15 showing that the model is significant. P-values less than 0.05 
confirm the significancy of the model. Model is not significant when 
values are greater than 0.1000. The Predicted R² of 0.8345 agrees with 
the Adjusted R² of 0.9710., the difference is less than 0.2. [27, 28]. 
ANOVA for entrapment efficiency (%) (Response 2) 
The result of P-values is 0.0003 (Significant) the Model F-value is 
45.06 showing that the model is significant. P-values less than 0.05 
confirm the significancy of the model. Model is not significant when 
values are greater than 0.1000. The Predicted R² of 0.8479 agrees 
with the Adjusted R² of 0.9659, the difference is less than 0.2 
Selection of the optimum formula 
Further in this study, the point prediction method of Box–Behnken 
design was utilized for the optimization of transfersomes 
formulation. The optimized formula desirability function comes 
higher ie near to 1 confirms the suitability of the formulations. 
Further, the zeta potential value of optimized formulation was 
found-37 mV, respectively. The optimized formulation so produced 
will be further evaluated for vesicle morphology, in vitro release 
study, skin irritation study, and in vivo study. 
 
Table 5: Experimental value obtained through point prediction method 
Composition Optimized level  Response Predicted value Experimental value* 
Naproxen sodium (mg) 20.74 Vesicle size (nm) 114.33 114.91 
Phosphatidylcholine (mg) 60.70 Entrapment efficiency (%) 79.69 80.11 
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Fig. 2: Transfersomes factorial design (Box Behnken) 
 
Vesicle size (nm): 2D contour plot (1A). 3D Surface Contour plot 
(1B). Cube Plot (1C) 
Entrapment efficiency (%):2D contour plot (2A). 3D Surface 
Contour plot (2B). Cube Plot (2C) 
CONCLUSION 
Present study utilizes a factorial design (Box Behnken) for the 
preparation of naproxen sodium transfersomes and transethosomes 
with desired characteristic responses. The factorial design describes 
the relationship between an experimental response and a set of 
input variables. Optimization of vesicles signifies a point prediction 
model for the selection of variable ranges to achieve the expected 
desired outcome and responses. Within a small experimental trial 
setup, the desired responses can be achieved by a systematic 
experimental formulation approach for establishing a mathematical 
trend in the experimental design. In our study, optimized 
formulations show minimum vesicle size, good entrapment 
efficiency, and optimum zeta potential, which justify the usefulness 
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